Ca2+ mobilization in saphenous vein smooth muscle cells derived from patients with primary varicosity

European Journal of Clinical Investigation

Volumn 32, Issue 9, 2002, Pages 649-656

  Schuller Petrovic, S ^a   Stessel, H ^b   Brunner, Friedrich ^b  

^a University Eye Clinic   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Angiotensin II; Cytosolic free Ca2+; Endothelin 1; Fura 2; Human primary varicosis; Saphenous vein contraction

Indexed keywords

ANGIOTENSIN; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; CARDIAC GLYCOSIDE; DIURETIC AGENT; ENDOTHELIN 1; FURA 2; NITRATE; PENTOXIFYLLINE; POLLEN EXTRACT; PROSTAFLOR; ANGIOTENSIN II; BRADYKININ; CALCIUM; THROMBIN; VASOCONSTRICTOR AGENT;

ANKLE; ARTICLE; CALCIUM MOBILIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; ENDOTHELIUM; FEMALE; HEART SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; INGUINAL REGION; KNEE; MALE; PHENOTYPE; PRIORITY JOURNAL; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; VARICOSIS; VISCOSITY; ADULT; CALCIUM SIGNALING; CASE CONTROL STUDY; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MIDDLE AGED; MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

ADULT; ANGIOTENSIN II; BRADYKININ; CALCIUM; CALCIUM SIGNALING; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; SAPHENOUS VEIN; THROMBIN; VARICOSE VEINS; VASOCONSTRICTOR AGENTS;

EID: 0036882346     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01023.x     Document Type: Article

References (37)

1. Tolins SH. Treatment of varicose veins. Am J Surg 1983;145:248-52.
2. Callam MJ. Epidemiology of varicose veins. Br J Surg 1994;81:167-73.
3. Leu AJ, Leu H-J, Franzeck UK, Bollinger A. Microvascular changes in chronic venous insufficiency - a review. Cardiovasc Surg 1995;3:237-45.
4. Watts GT. Varicose veins are caused by defective valves in the veins. Lancet 1986;i:31-2.
5. Thulesius O. Physiologic observations on causes of varicose veins. Int Angiol 1996;15:114-18.
6. Andreotti L, Cammelli D. Connective tissue in varicose veins. Angiology 1979;30:798-805.
7. Rose SS, Ahmed A. Some thoughts on the aetiology of varicose veins. J Cardiovasc Surg (Torino) 1986;27:534-43.
8. Michiels C, Arnould T, Remacle J. Hypoxia-induced activation of endothelial cells as a possible cause of venous diseases: hypothesis. Angiology 1993;44:639-46.
9. Thulesius O, Said S, Shuhaiber H, Neglen P, Gjores JE. Endothelial mediated enhancement of noradrenaline induced vasoconstriction in normal and varicose veins. Clin Physiol 1991;11:153-9.
10. Blöchl-Daum B, Schuller-Petrovic S, Wolzt M, Korn A, Böhler K, Eichler H-G. Primary defect in α-adrenergic responsiveness in patients with varicose veins. Clin Pharmacol Ther 1991;49:49-52.
11. Lowell R, Gloviczki P, Miller V. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992;16:679-86.
12. Schuller-Petrovic S, Siedler S, Kern T, Meinhart J, Schmidt K, Brunner F. Imbalance between the endothelial cell-derived contracting factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis. Br J Pharmacol 1997;122:772-8.
13. Kamm KE, Stull JT. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu Rev Pharmacol Toxicol 1985;25:593-620.
14. Yang Z, Arnet U, von Segesser L, Siebenmann R, Turina ML, Lüscher TF. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 1993;22 (Suppl. 5):S17-S22.
15. Li Q, Feenstra M, Pfaffendorf M, Eijsman L, van Zwieten PA. Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. J Cardiovasc Pharmacol 1997;29:451-6.
16. Yu JCM, Davenport AP. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol 1995;114:551-7.
17. Eguchi D, Nishimura J, Kobayashi S, Komori K, Sugimachi K, Kanaide H. Mechanism of contraction induced by bradykinin in the rabbit saphenous vein. Br J Pharmacol 1997;120:371-8.
18. Glusa E, Wolfram U. The contractile response of vascular smooth muscle to thrombin and its inhibition by thrombin inhibitors. Folia Haematol Int Mag Klin Morph Blutforsch 1988;115:94-100.
19. 2+-concentrations and cGMP-levels in endothelial cells. Cell Signal 1990;2:369-75.
20. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50.
21. Brunner F, Hoffmann C, Schuller-Petrovic S. Responsiveness of human varicose saphenous veins to vasoactive agents. Br J Clin Pharmacol 2001;51:219-24.
22. Barber DA, Wang X, Gloviczki P, Miller VM. Characterization of endothelin receptors in human varicose veins. J Vasc Surg 1997;26:61-9.
23. Rizzi A, Quaglio D, Vasquez G, Mascoli F, Amadesi S, Caló G et al. Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg 1998;28:855-61.
24. Munro E, Chan P, Patel M, Betteridge L, Gallagher K, Schachter M et al. Consistent responses of the human vascular smooth muscle cell in culture: implications for restenosis. J Vasc Surg 1994;20:482-7.
25. Assender JW, Irenius E, Fredholm BB. 5-Hydroxytryptamine, angiotensin and bradykinin transiently increase intracellular calcium concentrations and PKC-alpha activity, but do not induce mitogenesis in human vascular smooth muscle cells. Acta Physiol Scand 1997;160:207-17.
26. Zhu Z, Zhang SH, Wagner C, Kurtz A, Maeda N, Coffman T et al. Angiotensin AT1B receptor mediates calcium signaling in vascular smooth muscle cells of AT1A receptor-deficient mice. Hypertension 1998;31:1171-7.
27. Mizuno K, Niimura S, Tani M, Haga H, Inagami T, Fukuchii S. Direct proof for local generation and release of angiotensin II in peripheral human vascular tissue. Am J Hypertens 1991;4:67S-72S.
28. Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD, Yacoub MH. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg 1998;116:206-12.
29. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
30. Marsden PA, Danthuluri NR, Brenner BM, Ballermann BJ, Brock TA. Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization. Biochem Biophys Res Commun 1989;158:86-93.
31. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-46.
32. Dixon BS, Breckon R, Fortune J, Vavrek J, Stewart JM, Marzec-Calvert R et al. Effects of kinins on cultured arterial smooth muscle. Am J Physiol 1990;258:C299-C308.
33. 2 receptors and involvement of eicosanoids. Br J Pharmacol 1997;120:215-20.
34. Higman DJ, Greenhalgh RM, Powell JT. Smoking impairs endothelium-dependent relaxation of saphenous veins. Br J Surg 1993;80:1242-5.
35. Neylon CB, Hoyland J, Mason WT, Irvine RF. Spatial dynamics of intracellular calcium in agonist-stimulated vascular smooth muscle cells. Am J Physiol 1990;259:C675-C686.
36. Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Julmy F, Joch H et al. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels: implications for venous bypass graft failure. Circulation 1997;95:1870-6.
37. Luca S, Romeo S. Edema and skin ulcers of the lower limbs as a collateral effect of nifedipine. A clinical case report (in Italian). Minerva Cardioangiol 1999;47:219-22.